10358 Federal Register / Vol. 86, No. 32 / Friday, February 19, 2021 / Notices 

Controlled substance Drug code Schedule 

JWH-018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................. 7118 I 

JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ...................................................................................................... 7122 I 

UR-144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone .................................................................. 7144 I 

JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ...................................................................................................... 7203 I 

Ibogaine ........................................................................................................................................................................... 7260 I 

Lysergic acid diethylamide .............................................................................................................................................. 7315 I 

Marihuana Extract ........................................................................................................................................................... 7350 I 

Marihuana ........................................................................................................................................................................ 7360 I 

Tetrahydrocannabinols .................................................................................................................................................... 7370 I 

Mescaline ......................................................................................................................................................................... 7381 I 

JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ...................................................................................................... 7398 I 

3,4-Methylenedioxymethamphetamine ............................................................................................................................ 7405 I 

5-Methoxy-N–N-dimethyltryptamine ................................................................................................................................ 7431 I 

Psilocyn ........................................................................................................................................................................... 7438 I 

4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) ..................................................................................................... 7498 I 

MDPV (3,4-Methylenedioxypyrovalerone) ....................................................................................................................... 7535 I 

Methylone (3,4-Methylenedioxy-N-methylcathinone) ...................................................................................................... 7540 I 

Butylone ........................................................................................................................................................................... 7541 I 

Pentylone ......................................................................................................................................................................... 7542 I 

Codeine-N-oxide .............................................................................................................................................................. 9053 I 

Desomorphine ................................................................................................................................................................. 9055 I 

Dihydromorphine ............................................................................................................................................................. 9145 I 

Heroin .............................................................................................................................................................................. 9200 I 

Morphine-N-oxide ............................................................................................................................................................ 9307 I 

Normorphine .................................................................................................................................................................... 9313 I 

Tilidine ............................................................................................................................................................................. 9750 I 

Alpha-methylfentanyl ....................................................................................................................................................... 9814 I 

Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ............................................................................... 9821 I 

Methamphetamine ........................................................................................................................................................... 1105 II 

Phenmetrazine ................................................................................................................................................................. 1631 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Amobarbital ...................................................................................................................................................................... 2125 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

Secobarbital ..................................................................................................................................................................... 2315 II 

Glutethimide ..................................................................................................................................................................... 2550 II 

Phencyclidine ................................................................................................................................................................... 7471 II 

4-Anilino-N-phenethyl-4-piperidine (ANPP) ..................................................................................................................... 8333 II 

Norfentanyl ...................................................................................................................................................................... 8366 II 

Phenylacetone ................................................................................................................................................................. 8501 II 

Codeine ........................................................................................................................................................................... 9050 II 

Dihydrocodeine ................................................................................................................................................................ 9120 II 

Diphenoxylate .................................................................................................................................................................. 9170 II 

Ecgonine .......................................................................................................................................................................... 9180 II 

Ethylmorphine .................................................................................................................................................................. 9190 II 

Hydrocodone ................................................................................................................................................................... 9193 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Meperidine intermediate-B .............................................................................................................................................. 9233 II 

Meperidine intermediate-C .............................................................................................................................................. 9234 II 

Methadone intermediate .................................................................................................................................................. 9254 II 

Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. 9273 II 

Morphine .......................................................................................................................................................................... 9300 II 

Thebaine .......................................................................................................................................................................... 9333 II 

14-Hydroxmorphone ........................................................................................................................................................ 9665 II 

Noroxymorphone ............................................................................................................................................................. 9668 II 

Sufentanil ......................................................................................................................................................................... 9740 II 

Fentanyl ........................................................................................................................................................................... 9801 II 

The company plans to import the 

listed controlled substances for sale to 

research facilities for drug testing and 

analysis. In reference to drug codes 7360 

(Marihuana) and 7370 

(Tetrahydrocannabinols) the company 

plans to import a synthetic cannabidiol 

and a synthetic tetrahydrocannabinol. 

No other activities for these drug codes 

are authorized for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

William T. McDermott, 

Assistant Administrator. 

[FR Doc. 2021–03381 Filed 2–18–21; 8:45 am] 

BILLING CODE 4410–09–P 

NATIONAL AERONAUTICS AND 

SPACE ADMINISTRATION 

[Notice: (21–009)] 

NASA Astrophysics Advisory 

Committee; Meeting 

AGENCY: National Aeronautics and 

Space Administration. 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, Public 


tkelley on DSKBCP9HB2PROD with NOTICES
Federal Register / Vol. 86, No. 32 / Friday, February 19, 2021 / Notices 10359 

Law 92–463, as amended, the National 

Aeronautics and Space Administration 

(NASA) announces a meeting of the 

Astrophysics Advisory Committee. This 

Committee reports to the Director, 

Astrophysics Division, Science Mission 

Directorate, NASA Headquarters. The 

meeting will be held for the purpose of 

soliciting, from the scientific 

community and other persons, scientific 

and technical information relevant to 

program planning. 

DATES: Monday, March 15, 2021, 11:00 

a.m.–5:00 p.m.; Tuesday, March 16, 

2021, 11:00 a.m.–5:00 p.m.; and 

Wednesday, March 17, 2021, 11:00 

a.m.–5:00 p.m.; Eastern Time. 

FOR FURTHER INFORMATION CONTACT: Ms. 

KarShelia Henderson, Science Mission 

Directorate, NASA Headquarters, 

Washington, DC 20546, (202) 358–2355, 

or khenderson@nasa.gov. 

SUPPLEMENTARY INFORMATION: The 

meeting will be available to the public 

by WebEx. 

On Monday, March 15, the event 

address for attendees is: https://

nasaenterprise.webex.com/ 

nasaenterprise/j.php?MTID=md56c2364

ad7f625bf9121430ef9d85f9, the meeting 

number is 199 340 9228, and meeting 

password is MJh8JVDV89@. 

On Tuesday, March 16, the event 

address for attendees is: https://

nasaenterprise.webex.com/ 

nasaenterprise/j.php?MTID=

m1ce0a71960e457179b7e

85dcc41de62b, the meeting number is 

199 888 1998, and meeting password is 

csAvpYM2@78. 

On Wednesday, March 17, the event 

address for attendees is: https://

nasaenterprise.webex.com/ 

nasaenterprise/j.php?MTID=

m26744d6e150f086b3cf3ed99bd6649fa, 

the meeting number is 199 029 2743, 

and meeting password is 9skWYje8P@3. 

To join by telephone, the numbers 

are: 1–929–251–9612 or 1–415–527– 

5035, for each day. 

The agenda for the meeting includes 

the following topics: 

—Astrophysics Division Update 

—Updates on Specific Astrophysics 

Missions 

—Reports from the Program Analysis 

Groups 

—Reports from Specific Research and 

Analysis Programs 

The agenda will be posted on the 

Astrophysics Advisory Committee web 

page: https://science.nasa.gov/ 

researchers/nac/science-advisorycommittees/apac. 

The public may submit and upvote 

comments/questions ahead of the 

meeting through the website https://

arc.cnf.io/sessions/mkky/#!/dashboard 

that will be opened for input on March 

1, 2021. 

It is imperative that the meeting be 

held on this date to accommodate the 

scheduling priorities of the key 

participants. 

Patricia Rausch, 

Advisory Committee Management Officer, 

National Aeronautics and Space 

Administration. 

[FR Doc. 2021–03372 Filed 2–18–21; 8:45 am] 

BILLING CODE 7510–13–P 

NATIONAL SCIENCE FOUNDATION 

Advisory Committee for International 

Science and Engineering; Notice of 

Meeting 

In accordance with the Federal Advisory 

Committee Act (Pub. L. 92–463, as amended), 

the National Science Foundation (NSF) 

announces the following meeting: 

Name and Committee Code: Advisory 

Committee for International Science and 

Engineering Meeting (AC–ISE) (#25104). 

Date and Time: Friday, March 19, 

2021, 10:00 a.m. to 5:00 p.m. (Eastern 

Time). 

Place: NSF, 2415 Eisenhower Avenue, 

Alexandria, VA 22314 | Virtual Zoom. 

This AC–ISE meeting is fully virtual. 

All public participants are required to 

process the meeting registration via 

Zoom. 

Connect to The Virtual Meeting: 

Register in advance for the meeting at 

the Zoom attendee registration link: 

https://nsf.zoomgov.com/webinar/ 

register/WN_

IRrGAhXcRO2DvpdH7jAVjA. After 

registering, you will receive a 

confirmation email with a unique link 

to join the meeting. 

If you have any login questions, 

please contact Kirk Grabowski, OISE IT 

Specialist: kgrabows@associates.nsf.gov. 

Type of Meeting: Open. 

Contact Person: Christopher Street, 

National Science Foundation, 2415 

Eisenhower Avenue, Room W–17220, 

Alexandria, Virginia 22314; Telephone: 

(703) 292–8568/Email: cstreet@nsf.gov. 

Purpose of Meeting: To provide 

advice, recommendations and counsel 

on major goals and policies pertaining 

to international programs and activities. 

Agenda 

• Updates on OISE activities 

• Discussion on Global Leadership in 

Science, Engineering, and Education 

• Innovative Partnerships 

• Meet with NSF leadership 

Dated: February 16, 2021. 

Crystal Robinson, 

Committee Management Officer. 

[FR Doc. 2021–03389 Filed 2–18–21; 8:45 am] 

BILLING CODE 7555–01–P 

NATIONAL SCIENCE FOUNDATION 

Sunshine Act Meetings 

The National Science Board (NSB) hereby 

gives notice of the scheduling of meetings for 

the transaction of NSB business as follows: 

TIME AND DATE: Tuesday, February 23, 

2021, from 11:00 a.m. to 6:45 p.m., and 

Wednesday, February 24, 2021, from 

11:00 a.m. to 6:40 p.m. EST. 

PLACE: These meetings will be held by 

videoconference. There will be no inperson meetings. The public may 

observe the public meetings, which will 

be streamed to the NSF You Tube 

channel. For meetings on Tuesday, 

February 23, go to: https://youtu.be/ 

6JjWhwMhIKM. For meetings on 

Wednesday, February 24, go to: https:// 

youtu.be/tmiQwe7o_Y0. 

STATUS: Parts of these meetings will be 

open to the public. The rest of the 

meetings will be closed to the public. 

See full description below. 

MATTERS TO BE CONSIDERED: 

Tuesday, February 23, 2021 

Plenary Board Meeting 

Open Session: 11:00 a.m.–1:05 p.m. 

• NSB Chair’s Remarks 

• New Member Swearing-in 

Matthew Malkan 

Scott Stanley 

• NSF Director’s Remarks 

• NSB Chair Activity Summary 

• Racial Equity Task Force and NSF 

Harassment Policy Update 

• Vision 2030 Implementation Working 

Group Update 

Committee on Oversight (CO) 

Open Session: 1:15 p.m.–2:25 p.m. 

• Committee Chair’s Opening Remarks 

• Approval of Committee Meeting 

Minutes 

• Broader Impacts—Update on 

Activities 

Discussion and action on statement 

and resolution re: Reviewer 

Training 

Discussion and action on statement 

and resolution re: Broader Impacts 

Expert on Committees of Visitors 

• Inspector General’s Update 

• Chief Financial Officer’s Update 

Committee on National Science and 

Engineering Policy (SEP) 

Open Session: 2:35 p.m.–3:25 p.m. 

• Committee Chair’s Opening Remarks 


tkelley on DSKBCP9HB2PROD with NOTICES